Inclusion Criteria:

          -  Males or females aged ≥ 18 years.

          -  Ability to understand and willingness to sign a written informed consent document.

          -  Patients must have a histologically or cytologically confirmed metastatic or
             unresectable malignancy.

          -  Estimated life expectancy, in the judgment of the Investigator, of at least 90 days.

          -  Adequate bone marrow, liver, and renal functions.

          -  Men and women of childbearing potential must agree to take highly effective
             contraceptive methods.

          -  Patients should recover from all reversible AEs of previous anticancer therapies to
             baseline.

          -  Patients infected with the HIV virus will be eligible if the disease is under control
             of effective therapy.

        Exclusion Criteria:

          -  Receipt of systemic anticancer therapy including investigational agents or devices
             within 5 half-lives of the first dose of study treatment.

          -  Previous radiotherapy within 14 days of the first dose of study treatment.

          -  Known active CNS metastasis and/or carcinomatous meningitis.

          -  Has received a live-virus vaccine within 30 days.

          -  Has had a Grade ≥ 3 allergic reaction to treatment with a monoclonal antibody.

          -  Abnormality of QT interval or syndrome.

          -  Patients with history of Grade ≥ 3 immune-related AEs (irAEs) or irAE.

          -  Patients who are receiving an immunologically-based treatment for any reason.

          -  Treatment with systemic immune-stimulatory agents within 4 weeks prior to the first
             dose of study drug.

          -  Active or chronic autoimmune disease that has required systemic treatment in the past
             2 years or who are receiving systemic therapy for an autoimmune or inflammatory
             disease.

          -  Has a clinically significant cardiac condition, including unstable angina, acute
             myocardial infarction within 6 months.

          -  Has an active infection requiring intravenous (i.v.) anti-infectives within 14 days
             before the first dose of study treatment.

          -  Current evidence or history of interstitial lung disease or active, noninfectious
             pneumonitis requiring treatment such as oral or intravenous glucocorticoids to assist
             with management.

          -  Female patients who are pregnant or breastfeeding.

          -  Any evidence of severe or uncontrolled systemic disease.

          -  Any other disease or clinically significant abnormality in laboratory parameters.

          -  Has previously had a stem cell or bone marrow or solid organ transplant.